Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers at George Washington University take a look.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Tenofovir disoproxil fumarate is found in Truvada, Viread, Atripla, Complera and Stribild.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
That’s compared with HIV-negative men.
Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.
A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.
Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.